Baxter 1B6626P - Travasol (Amino Acid), 10% Injection, 2000 ml, Viaflex Plastic Container, Not for Direct Infusion, Bulk, 6/cs (Rx) (Continental US Only, Excluding IN and ND)
Baxter 1B6626P 10% TRAVASOL Injection, 500 mL in VIAFLEX Container
TRAVASOL is indicated as a source of amino acids for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. TRAVASOL may be used to treat negative nitrogen balance in patients.
TRAVASOL 10% is a sterile solution of 10 grams of amino acids per 100 mL (0.1 gram/mL) available in 500 mL, 1000 mL, and 2000 mL flexible containers, which contain essential and nonessential amino acids. describes the individual components of TRAVASOL.
TRAVASOL Injection is a sterile, hypertonic solution that is designed for intravenous use. It is an essential part of parenteral nutrition, providing a source of amino acids for patients who are unable to consume nutrients through their digestive system. TRAVASOL Injection is commonly used in clinical settings to address the nutritional needs of patients who require specialized nutritional support.
Composition: TRAVASOL Injection primarily consists of amino acids, which are the building blocks of proteins. These amino acids are essential for various bodily functions, including tissue repair, immune system support, and enzyme production.
Indications: TRAVASOL Injection is typically prescribed for patients who cannot receive sufficient nutrients through oral or enteral (tube feeding) routes. This includes individuals with gastrointestinal disorders, severe malabsorption, or those who are undergoing surgery and need additional nutritional support.
Amino Acid Profile: The formulation of TRAVASOL Injection includes a carefully balanced mixture of essential and non-essential amino acids. This helps provide a comprehensive source of protein precursors that the body can use to synthesize the proteins it needs.
Hypertonic Solution: TRAVASOL Injection is hypertonic, meaning it has a higher concentration of solutes (substances dissolved in the solution) compared to bodily fluids. This characteristic requires careful administration and monitoring to prevent potential complications.
Medical Supervision: The use of TRAVASOL Injection requires medical supervision and should be administered by trained healthcare professionals. The dosing regimen and infusion rate are determined based on the patient's individual nutritional needs and medical condition.
Compatibility: TRAVASOL Injection may be used in combination with other parenteral nutrition components, such as lipid emulsions, electrolytes, vitamins, and minerals, to provide a comprehensive nutritional solution.
Patient Monitoring: Patients receiving TRAVASOL Injection should be closely monitored for any signs of adverse reactions, fluid and electrolyte imbalances, and metabolic changes. Regular assessments help ensure that the patient's nutritional needs are being met effectively.
